Accumulated Amyloid-β Peptide and Hyperphosphorylated Tau Protein: Relationship and Links in Alzheimer's Disease
The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Abstract
The neuropathology associated with Alzheimer's disease (AD) is characterized by the presence of extracellularly neuritic plaques, intracellularly neurofibrillary tangles and the loss of basal forebrain cholinergic neurons. The neuritic plaque is composed of a core of amyloid-beta peptide (Abeta) while the neurofibrillary tangles contain phosphorylated tau protein, and, as such, both Abeta and tau are important molecules associated with AD. In healthy human bodies, clearance mechanisms for Abeta are available; yet if clearance fails, Abeta accumulates, increasing the risk of neurotoxicity in the brain. Tau, one of the main microtubule-associated proteins, will be hyperphosphorylated and lose the ability to bind microtubules when the homeostasis of phosphorylation and dephosphorylation is disturbed in neurons. Accumulated Abeta and hyperphosphorylated tau are thought to be coexistent. Research on the pathological changes in AD indicates that accumulated Abeta in vivo may initiate the hyperphosphorylation of tau. Also, the signal transduction pathways of tau hyperphosphorylation may be related to accumulated Abeta. In this review, we will discuss how Abeta accumulates, how tau protein is hyperphosphorylated, and how accumulated Abeta initiates hyperphosphorylation of tau protein in AD.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Matrix Metalloproteinase-9 Degrades Amyloid-β Fibrils in Vitro and Compact Plaques in Situ
Yan, P., Hu, X., Song, H., Yin, K., Bateman, R. J., Cirrito, J. R., Xiao, Q., Hsu, F. F., Turk, J. W., Xu, J., et al. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m602440200 · Cited by 380 · cited 1×
“…neprilysin(NEP) [25,26],endothelincon-verting enzyme (ECE)-1 [27], insulin degrading enzyme (IDE) [28,29], angiotensin converting enzyme (ACE) [30], cathepsin D [31], gelatinase A [32], matrix metalloendopeptidase-9 (MMP-9) [33], coagulation factor XIa [34] and α 2-macroglobulin complexes [35].”
Eckman, E. A., Adams, S. K., Troendle, F. J., Stodola, B. A., Kahn, M. A., Fauq, A. H., Xiao, H. D., Bernstein, K. E., & Eckman, C. B. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m605827200 · Cited by 196 · cited 1×
“But Eckman and colleagues [40] showed that the concentration of Aβ in Aβ-accumulated mice brains does not change when mice were treated with ACE inhibitors and that the steady-state Aβ levels did not alter in brains of ACE deficient mice.”
Cited by
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
Turner, M. D., Nedjai, B., Hurst, T., & Pennington, D. J. (2014) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2014.05.014 · Cited by 2,162
Ketamine and Ketamine Metabolite Pharmacology: Insights into Therapeutic Mechanisms
Zanos, P., Moaddel, R., Morris, P. J., Riggs, L. M., Highland, J. N., Georgiou, P., Pereira, E. F. R., Albuquerque, E. X., Thomas, C. J., Zarate, C. A., et al. (2018) · Pharmacological Reviews · doi:10.1124/pr.117.015198 · Cited by 1,260
Basic mechanisms of neurodegeneration: a critical update
Jellinger, K. A. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01010.x · Cited by 596
Drug treatments in Alzheimer’s disease
Briggs, R., Kennelly, S. P., & O’Neill, D. (2016) · Clinical Medicine · doi:10.7861/clinmedicine.16-3-247 · Cited by 571
Neuropathology of sporadic Parkinson's disease: Evaluation and changes of concepts
Jellinger, K. A. (2012) · Movement Disorders · doi:10.1002/mds.23795 · Cited by 451
Metal dyshomeostasis and oxidative stress in Alzheimer’s disease
Greenough, M. A., Camakaris, J., & Bush, A. I. (2013) · Neurochemistry International · doi:10.1016/j.neuint.2012.08.014 · Cited by 436
Mao, P., & Reddy, P. H. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.08.005 · Cited by 313
Lee, H. J., Lee, J. K., Lee, H., Carter, J. E., Chang, J. W., Oh, W., Yang, Y. S., Suh, J.-G., Lee, B.-H., Jin, H. K., et al. (2012) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2010.03.024 · Cited by 283
Insulin signaling pathway and related molecules: Role in neurodegeneration and Alzheimer's disease
Akhtar, A., & Sah, S. P. (2020) · Neurochemistry International · doi:10.1016/j.neuint.2020.104707 · Cited by 279
Recent advances in our understanding of neurodegeneration
Jellinger, K. A. (2009) · Journal of Neural Transmission · doi:10.1007/s00702-009-0240-y · Cited by 274
“Accumulation of Ab and phosphotau are thought to be coexistent, Ab initiating hyperphosphorylation of tau (Huang and Jiang 2009).”
BackgroundEpigenetic regulation in the pathophysiology of Alzheimer's disease
Chouliaras, L., Rutten, B. P. F., Kenis, G., Peerbooms, O., Visser, P. J., Verhey, F., van Os, J., Steinbusch, H. W. M., & van den Hove, D. L. A. (2010) · Progress in Neurobiology · doi:10.1016/j.pneurobio.2010.01.002 · Cited by 262
Neurological Disease as a Failure of Brain-Immune Crosstalk: The Multiple Faces of Neuroinflammation
Schwartz, M., & Deczkowska, A. (2016) · Trends in Immunology · doi:10.1016/j.it.2016.08.001 · Cited by 246
Scuderi, C., Steardo, L., & Esposito, G. (2014) · Phytotherapy Research · doi:10.1002/ptr.5095 · Cited by 161
Amyloid-β and Tau in Alzheimer’s disease: pathogenesis, mechanisms, and interplay
Abdulkhaliq, A. A., Kim, B., Almoghrabi, Y. M., Khan, J., Ajoolabady, A., Ren, J., Bahijri, S., Tuomilehto, J., Borai, A., & Pratico, D. (2026) · Cell Death & Disease · doi:10.1038/s41419-025-08186-8 · Cited by 87
Selection of Candidate Housekeeping Genes for Normalization in Human Postmortem Brain Samples
Penna, I., Vella, S., Gigoni, A., Russo, C., Cancedda, R., & Pagano, A. (2011) · International Journal of Molecular Sciences · doi:10.3390/ijms12095461 · Cited by 79
“3) protein neurofibrillary tangles and to the extracellular deposition of β-amyloid peptide (Aβ) in form of senile plaques [1].”
BackgroundCai, B., Wang, Y., Shao, J., Wang, T.-T., Cai, R.-Z., Ma, C.-J., Han, T., & Du, J. (2016) · Neural Regeneration Research · doi:10.4103/1673-5374.187056 · Cited by 52
“The main cause of neuronal death appears to be an abnormal increase and accumulation of Aβ in brain tissue (Huang and Jiang 2008; Duyckaerts et al., 2009; Rugarli and Langer 2012).”
BackgroundPathophysiological function of ADAMTS enzymes on molecular mechanism of Alzheimer’s disease
Gurses, M. S., Ural, M. N., Gulec, M. A., Akyol, O., & Akyol, S. (2016) · Aging and disease · doi:10.14336/ad.2016.0111 · Cited by 35
“A lot of Aβ peptides will gather and form senile plaques in neurons [23].”
BackgroundInfluentialBae, D., Seol, H., Yoon, H.-G., Na, J.-R., Oh, K., Choi, C. Y., Lee, D.-W., Jun, W., Youl Lee, K., Lee, J., et al. (2012) · Pharmaceutical Biology · doi:10.3109/13880209.2011.642886 · Cited by 35
“It is clinically associated with cognitive impairment, loss of language and motor skills as well as changes in behavior (Huang & Jiang, 2009).”
BackgroundHaptoglobin Modulates Beta-Amyloid Uptake by U-87 MG Astrocyte Cell Line
Maresca, B., Spagnuolo, M. S., & Cigliano, L. (2015) · Journal of Molecular Neuroscience · doi:10.1007/s12031-014-0465-6 · Cited by 20
“Major neuropathological and neurochemical hallmarks of AD include the extracellular accumulation of amyloid-β peptide (Aβ) in brain senile plaques and the intracellular formation of neurofibrillary tangles composed of hyperphosphorylated Tau protein (Huang and Jiang 2009).”
BackgroundResearch Mechanism and Progress of the Natural Compound Curcumin in Treating Alzheimer’s Disease
Li, L., Wang, F., Jia, X., Yao, L., & Liu, Y. (2024) · Mini-Reviews in Medicinal Chemistry · doi:10.2174/0113895575263783231009051957 · Cited by 11
Metadata
- Authors
- Huang, H.-C., & Jiang, Z.-F.
- Venue
- Journal of Alzheimer's Disease
- Publisher
- SAGE Publications
- Published
- 2009-01-04
- Volume
- 16
- Issue
- 1
- Pages
- 15-27
- ISSN
- 1387-2877 (ISSN-L)
- 1875-8908
- OpenAlex
- W1484463237
- Cited by
- 279
- References
- 2
- FWCI
- 11.81
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.